Synbio International Inc. Expands its Board of Directors and Strengthens its Clinical Leadership with the Appointment of Dr. Nick Vatakis

Rhea-AI Summary

Synbio International (OTC: SYIN) appointed Dr. Nick Vatakis, MD as Medical Director and added him to its Board of Directors on October 22, 2025. Dr. Vatakis brings nearly 30 years of clinical and research experience, having served as principal investigator on over 200 clinical trials and previously founding and serving as CMO of a clinical research organization.

He will oversee the design and execution of Synbio’s upcoming feasibility trial for its AI-driven facial analysis depression screening software, with responsibility for ethical, medical, and scientific standards. Management states the appointment is intended to strengthen clinical rigor, regulatory credibility, and commercialization efforts.

Dr. Vatakis, appointed as Medical Director, brings decades of clinical trial leadership, advancing Synbio’s credibility and the integrity of its upcoming feasibility trial

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Synbio International Inc. (OTC: SYIN) (“Synbio” or the “Company”) is proud to announce the appointment of Dr. Nick Vatakis, MD as Medical Director. This appointment represents a major milestone in Synbio’s commitment to scientific excellence, clinical rigor, and the successful validation of its AI-driven facial analysis screening technology for depression.

Synbio welcomes Dr. Nick Vatakis, MD, a distinguished psychiatrist with nearly 30 years of clinical and research experience, to its Board of Directors. Dr. Vatakis is a recognized expert in psychopharmacology and integrative multimodal psychotherapy. Over his career, he has served as principal investigator on more than 200 clinical trials across a broad range of psychiatric and neurological conditions. Dr. Vatakis has also advised numerous drug development programs and served as founder and CMO of a clinical research organization in Eastern Europe. His extensive clinical and research expertise, coupled with his business consulting experience, will be pivotal as Synbio advances the validation and commercialization of the AI-driven facial analysis medical technology.

With his deep understanding of clinical science and trial operations, Dr. Vatakis’s involvement will be pivotal to Synbio’s credibility and success as the Company prepares to commence its feasibility trial of the facial analysis depression screening software. He will oversee the study’s design and execution, ensuring full adherence to the highest ethical, medical, and scientific standards.

Claudio Solitario, CEO of Synbio International Inc

“We are privileged to welcome Nick to Synbio’s leadership team,” said Claudio Solitario, CEO of Synbio International Inc. “Nick’s vast experience in clinical research and psychiatry not only strengthens the integrity of our feasibility trial, but also enhances our credibility with regulators, partners, and investors alike. His appointment marks a critical step in our journey toward clinical validation and commercialization of the facial analysis medical technology. I’m thrilled to have Nick join our Board.”

About Synbio International Inc.

Synbio International Inc. (OTC: SYIN) is a company focused on clinically validated AI-driven medical diagnostics. Through strategic partnerships and research collaborations, Synbio aims to bridge the gap between wellness and medicine, developing science-based solutions that improve quality of life and empower healthcare providers.

For media inquiries, please contact:
Synbio International Inc.
info@synbiointl.com
(646) 359-4854
www.synbiointl.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements in this press include, among others, statements about our renegotiated settlement agreement. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our limited operating history; our dependence on third parties for many aspects of our business; general market and economic conditions; technical factors; the availability of outside capital; our receipt of revenues; legislative developments; changes in our expenditures and other uses of cash; our ability to find, recruit and retain personnel in sufficient numbers to support our growth; our ability to manage growth; and general market, economic and business conditions. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/81261243-8f94-4ccf-b590-89f397e5f207

FAQ

Who is Dr. Nick Vatakis and what role did Synbio (SYIN) assign him on October 22, 2025?

Dr. Nick Vatakis is a psychiatrist with nearly 30 years of clinical and research experience; Synbio appointed him Medical Director and added him to the Board of Directors.

What will Dr. Nick Vatakis oversee at Synbio (SYIN)?

He will oversee the design and execution of the company’s feasibility trial for its AI-driven facial analysis depression screening software.

How does Synbio (SYIN) say Dr. Vatakis’s experience supports its clinical program?

The company cites his record as principal investigator on over 200 clinical trials and his clinical research leadership as strengthening clinical rigor and regulatory credibility.

When did Synbio (SYIN) announce the appointment of Dr. Nick Vatakis?

The appointment was announced on October 22, 2025.

What impact does Synbio (SYIN) expect from adding Dr. Vatakis to its Board?

The company expects his appointment to enhance scientific integrity, credibility with regulators and partners, and support validation and commercialization of the facial analysis technology.